Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference

    Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare
                                  Conference

PR Newswire

HAYWARD, Calif., Nov. 27, 2013

HAYWARD, Calif., Nov. 27, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH), a biopharmaceutical company focused on developing and
commercializing products to treat autoimmune diseases, announced today that
Paul F. Truex, President and Chief Executive Officer, and May Liu, Senior Vice
President of Finance and Administration, will present a corporate update at
the 2013 Annual Piper Jaffray Healthcare Conference.

Anthera will present at 4:00PM ET, December 3^rd, at the Palace Hotel in New
York City.

About Blisibimod

Anthera is developing blisibimod, a selective inhibitor of B-cell activating
factor (BAFF), to explore its clinical utility in various autoimmune diseases
including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod
is a novel fusion protein, or peptibody, and is distinct from an antibody.
Anthera owns worldwide rights to blisibimod in all potential indications.
BAFF, also known as BLyS (B lymphocyte stimulator), is a tumor necrosis family
member and is critical to the development, maintenance and survival of
B-cells. B-cells represent a critical component of human immune response to
infection and other pathogens.However, abnormal elevations of B-cells and
BAFF may lead to an overactive immune response which may damage normal healthy
tissues and organ systems. Multiple clinical studies with BAFF antagonists
have reported the potential benefit of BAFF inhibitors in treating patients
with lupus and rheumatoid arthritis.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on
developing and commercializing products to treat autoimmune
diseases.Anthera's Phase 3 development product candidate, blisibimod, targets
elevated levels of B-cell activating factor, or BAFF, which has been
associated with a variety of B-cell mediated autoimmune diseases, including
systemic lupus erythematosus (SLE), or lupus, Immunoglobin A nephropathy, or
IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic
thrombocytopenia purpura, and others.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on Anthera's expectations as of the date of this press
release and are subject to certain risks and uncertainties that could cause
actual results to differ materially as set forth in Anthera's public filings
with the SEC, including Anthera's Annual Report on Form 10-K for the year
ended December 31, 2012. Anthera disclaims any intent or obligation to update
any forward-looking statements, whether because of new information, future
events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or
510.856.5598.

SOURCE Anthera Pharmaceuticals, Inc.

Website: http://www.anthera.com
 
Press spacebar to pause and continue. Press esc to stop.